Laurus Labs FY26 revenue rises 23% to Rs 6,813 Crore; EBITDA surges 64%

Strong CDMO growth, improved product mix and operational leverage drive profitability expansion

Laurus Labs Q4 FY25 PAT up 208% to Rs. 234 Cr

The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25

Laurus Labs invests in Laurus Bio

Laurus Labs inaugurates Rs. 250 crore R&D facility in Telangana

Total investment incurred for setting up the new R&D Rs 250 crore

Laurus Labs inks JV agreement with KRKA, Slovenia

The registered capital of the newly founded company is € 50 million

ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'

NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy

Laurus Labs signs MOA with IIT Kanpur for novel gene therapy assets

Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets

Laurus Labs to increase stake in ImmunoACT to 33.86%

This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19

Laurus Labs receives USFDA tentative approval for Dolutegravir 5mg and 10mg in HIV/AIDS treatment

It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment

Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr

Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects